As artificial intelligence (AI), machine learning, and data-heavy applications continue to grow, the pressure they add to today's data centres is becoming clearer.
The illegal mining of the Amazon rainforest continues through the COVID pandemic, with Indigenous communities experiencing the double-hit of mercury poisoning and "imminent violence".
When rethinking service transformation, the focus should be on reshaping - Christopher Sly, AVP, Digital Transformation, HGS UK, explains why knowing the limitations to emerging tech reshapes a far greater value story.
The US is facing a fourth wave of COVID-19, as emergency healthcare workers across the country continue to face the virus and experience levels of burnout that can lead to PTSD.
New CDC guidelines suggest that surfaces are a "low-risk" for COVID transmission - cleaning surfaces with detergent or soap once a day should be enough to reduce possible virus levels.
Chris Norton, Managing Director, UK & Ireland, InterSystems, discusses the NHS’ current challenges, integrated care efforts, and the ways data and technology can be harnessed to inform care today, and in a post-COVID world.
Today (8 April) it was revealed that over 700,000 AstraZeneca doses manufactured in the UK are being sent to Australia - with a confirmed 300,000 vaccines in Sydney at the end of February.
New data from the REACT study finds that the prevalence of COVID is down by 60% in one month, but primary school children have the highest COVID infection levels.
Scientists have developed an implantable sensor using gold nanoparticles, which can function in the human body for "several months" to report health changes.
Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.
Adrian Crawley, VP of Synack’s EMEA region, looks at the challenges ‘green’ measures place on cybersecurity protections, vehicle safety, data, city planning, personal information and payments and how a collaborative approach is needed to overcome them.
Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.
